Comparing MyoKardia (MYOK) & Recro Pharma (REPH)

MyoKardia (NASDAQ: MYOK) and Recro Pharma (NASDAQ:REPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Valuation & Earnings

This table compares MyoKardia and Recro Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
MyoKardia $43.35 million 29.33 -$18.78 million ($0.69) -58.51
Recro Pharma $69.99 million 1.97 -$13.04 million ($2.21) -3.28

Recro Pharma has higher revenue and earnings than MyoKardia. MyoKardia is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for MyoKardia and Recro Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MyoKardia 0 0 4 0 3.00
Recro Pharma 0 1 5 0 2.83

MyoKardia presently has a consensus price target of $43.25, suggesting a potential upside of 7.12%. Recro Pharma has a consensus price target of $14.75, suggesting a potential upside of 103.45%. Given Recro Pharma’s higher possible upside, analysts clearly believe Recro Pharma is more favorable than MyoKardia.

Risk and Volatility

MyoKardia has a beta of 6.1, suggesting that its stock price is 510% more volatile than the S&P 500. Comparatively, Recro Pharma has a beta of -0.6, suggesting that its stock price is 160% less volatile than the S&P 500.

Profitability

This table compares MyoKardia and Recro Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MyoKardia -44.65% -16.35% -12.16%
Recro Pharma -46.75% -56.04% -19.40%

Institutional & Insider Ownership

47.6% of MyoKardia shares are owned by institutional investors. Comparatively, 63.7% of Recro Pharma shares are owned by institutional investors. 46.1% of MyoKardia shares are owned by insiders. Comparatively, 21.6% of Recro Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

MyoKardia beats Recro Pharma on 8 of the 13 factors compared between the two stocks.

MyoKardia Company Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Recro Pharma Company Profile

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply